Oxidative stress and schizophrenia: Recent breakthroughs from an old story

Current Opinion in Psychiatry

Volumn 27, Issue 3, 2014, Pages 185-190

  Emiliani, Francesco E ^a   Sedlak, Thomas W ^a   Sawa, Akira ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

glutathione; magnetic resonance spectroscopy; olfactory cell; oxidative stress; superoxide dismutase

Indexed keywords

EXCITATORY AMINO ACID TRANSPORTER 3; GLUTATHIONE DISULFIDE; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE; HYDROGEN PEROXIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE DISMUTASE;

BEHAVIOR CHANGE; ENDOPHENOTYPE; FRONTAL CORTEX; HOMEOSTASIS; HUMAN; IMMUNOREACTIVITY; INTERNEURON; NEGATIVE SYNDROME; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ORBITAL CORTEX; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PSYCHOSIS; REVIEW; SCHIZOPHRENIA;

ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; MICE; OXIDATIVE STRESS; SCHIZOPHRENIA;

EID: 84897113069     PISSN: 09517367     EISSN: 14736578     Source Type: Journal    
DOI: 10.1097/YCO.0000000000000054     Document Type: Review

References (60)

1. McGrath JJ, Mortensen PB, Visscher PM, et al. Where GWAS and epidemiology meet: opportunities for the simultaneous study of genetic and environmental risk factors in schizophrenia. Schizophr Bull 2013; 39:955-959.
2. Owen MJ, Craddock N, O'Donovan MC. Suggestion of roles for both common and rare risk variants in genome-wide studies of schizophrenia. Arch Gen Psychiatry 2010; 67:667-673.
3. Hoskins RG. Oxygen metabolism in schizophrenia. Arch Neurol Psychiatry 1937; 38:1261-1270.
4. Paschos A, Pandya R, Duivenvoorden WC, et al. Oxidative stress in prostate cancer: changing research concepts towards a novel paradigm for prevention and therapeutics. Prostate Cancer Prostatic Dis 2013; 16:217-225.
5. Elnakish MT, Hassanain HH, Janssen PM, et al. Emerging role of oxidative stress in metabolic syndrome and cardiovascular diseases: important role of Rac/NADPH oxidase. J Pathol 2013; 231:290-300.
6. Simonian NA, Coyle JT. Oxidative stress in neurodegenerative diseases. Annu Rev Pharmacol Toxicol 1996; 36:83-106. (Pubitemid 26168695)
7. Behrens MM, Ali SS, Dao DN, et al. Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase. Science 2007; 318:1645-1647. (Pubitemid 350233667)
8. Brennand KJ, Landek-Salgado MA, Sawa A. Modeling heterogeneous patients with a clinical diagnosis of schizophrenia with induced pluripotent stem cells. Biol Psychiatry 2013. [Epub ahead of print]
9. Cascella NG, Takaki M, Lin S, et al. Neurodevelopmental involvement in schizophrenia: the olfactory epithelium as an alternative model for research. J Neurochem 2007; 102:587-594. (Pubitemid 47057306)
10. Mackay-Sim A. Concise review: patient-derived olfactory stem cells: new models for brain diseases. Stem Cells 2012; 30:2361-2365.
11. Horiuchi Y, Kano S, Ishizuka K, et al. Olfactory cells via nasal biopsy reflect the developing brain in gene expression profiles: utility and limitation of the surrogate tissues in research for brain disorders. Neurosci Res 2013; 77:247-250.
12. Gillard JH, Waldman AD, Barker PB. ClinicalMR neuroimaging: physiological and functional techniques. 2nd ed. New York: Cambridge University Press; 2009.
13. Flatow J, Buckley P, Miller BJ. Meta-analysis of oxidative stress in schizophrenia. Biol Psychiatry 2013; 74:400-409.
14. McGorry P, Johanessen JO, Lewis S, et al. Early intervention in psychosis: keeping faith with evidence-based healthcare. Psychol Med 2010; 40:399-404.
15. Valko M, Leibfritz D, Moncol J, et al. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007; 39:44-84. (Pubitemid 44566469)
16. Robicsek O, Karry R, Petit I, et al. Abnormal neuronal differentiation and mitochondrial dysfunction in hair follicle-derived induced pluripotent stem cells of schizophrenia patients. Mol Psychiatry 2013; 18:1067-1076.
17. Kano S, Colantuoni C, Han F, et al. Genome-wide profiling of multiple histone methylations in olfactory cells: further implications for cellular susceptibility to oxidative stress in schizophrenia. Mol Psychiatry 2013; 18:740-742.
18. Gawryluk JW, Wang JF, Andreazza AC, et al. Decreased levels of glutathione, the major brain antioxidant, in postmortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol 2011; 14:123-130.
19. Yao JK, Leonard S, Reddy RD. Increased nitric oxide radicals in postmortem brain from patients with schizophrenia. Schizophr Bull 2004; 30:923-934. (Pubitemid 40469526)
20. Evans DR, Parikh VV, Khan MM, et al. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins Leukot Essent Fatty Acids 2003; 69:393-399. (Pubitemid 37464048)
21. Coughlin JM, Ishizuka K, Kano SI, et al. Marked reduction of soluble superoxide dismutase-1 (SOD1) in cerebrospinal fluid of patients with recent-onset schizophrenia. Mol Psychiatry 2013; 18:10-11.
22. Martinez-Cengotitabengoa M, Mac-Dowell KS, Leza JC, et al. Cognitive impairment is related to oxidative stress and chemokine levels in first psychotic episodes. Schizophr Res 2012; 137:66-72.
23. Raffa M, Mechri A, Othman LB, et al. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33:1178-1183.
24. Raffa M, Atig F, Mhalla A, et al. Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients. BMC Psychiatry 2011; 11:124.
25. Borgmann-Winter KE, Rawson NE, Wang HY, et al. Human olfactory epithelial cells generated in vitro express diverse neuronal characteristics. Neuroscience 2009; 158:642-653.
26. Paulsen S, de Moraes Maciel R, Galina A, et al. Altered oxygen metabolism associated to neurogenesis of induced pluripotent stem cells derived from a schizophrenic patient. Cell Transplant 2012; 21:1547-1559.
27. Trabesinger AH, Weber OM, Duc CO, et al. Detection of glutathione in the human brain in vivo by means of double quantum coherence filtering. Magn Reson Med 1999; 42:283-289. (Pubitemid 29364707)
28. Schwerk A, Alves FD, Pouwels PJ, et al. Metabolic alterations associated with schizophrenia: a critical evaluation of proton magnetic resonance spectroscopy studies. J Neurochem 2014; 128:1-87.
29. Do KQ, Trabesinger AH, Kirsten-Kruger M, et al. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci 2000; 12:3721-3728.
30. 1H NMR spectroscopy at 4T: application to schizophrenia. MAGMA 2005; 18:276-282. (Pubitemid 41738416)
31. 1H-MRS study. PLoS One 2008; 3:e1944.
32. 1H-MRS investigation. Neurobiol Dis 2009; 33:354-357.
33. Terpstra M, Henry PG, Gruetter R. Measurement of reduced glutathione (GSH) in human brain using LCModel analysis of difference-edited spectra. Magn Reson Med 2003; 50:19-23. (Pubitemid 36841855)
34. Gonzalez-Burgos G, Lewis DA. NMDA receptor hypofunction, parvalbuminpositive neurons, and cortical gamma oscillations in schizophrenia. Schizophr Bull 2012; 38:950-957.
35. Benes FM, Berretta S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 2001; 25:1-27. (Pubitemid 32493819)
36. Akbarian S, Kim JJ, Potkin SG, et al. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry 1995; 52:258-266.
37. Lodge DJ, Behrens MM, Grace AA. A loss of parvalbumin-containing interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia. J Neurosci 2009; 29:2344-2354.
38. Uhlhaas PJ, Singer W. Abnormal neural oscillations and synchrony in schizophrenia. Nat Rev Neurosci 2010; 11:100-113.
39. Johnson AW, Jaaro-Peled H, Shahani N, et al. Cognitive and motivational deficits together with prefrontal oxidative stress in a mouse model for neuropsychiatric illness. Proc Natl Acad Sci USA 2013; 110:12462-12467.
40. 2 in the development of behavioral and pathologic alterations in isolated rats. Biol Psychiatry 2009; 66:384-392.
41. Cabungcal JH, Steullet P, Kraftsik R, et al. Early-life insults impair parvalbumin interneurons via oxidative stress: reversal by N-acetylcysteine. Biol Psychiatry 2012; 73:574-582.
42. Konat GW, Wiggins RC. Effect of reactive oxygen species on myelin membrane proteins. J Neurochem 1985; 45:1113-1118. (Pubitemid 16258156)
43. Takahashi N, Sakurai T, Davis KL, et al. Linking oligodendrocyte and myelin dysfunction to neurocircuitry abnormalities in schizophrenia. Prog Neurobiol 2011; 93:13-24.
44. Martins-de-Souza D, Gattaz WF, Schmitt A, et al. Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis. J Neural Transm 2009; 116:275-289.
45. Paintlia MK, Paintlia AS, Khan M, et al. Modulation of peroxisome proliferator activated receptor-alpha activity by N-acetyl cysteine attenuates inhibition of oligodendrocyte development in lipopolysaccharide stimulated mixed glial cultures. J Neurochem 2008; 105:956-970. (Pubitemid 351562737)
46. Tristan C, Shahani N, Sedlak TW, et al. The diverse functions of GAPDH: views from different subcellular compartments. Cell Signal 2011; 23:317-323.
47. Gysin R, Kraftsik R, Sandell J, et al. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc Natl Acad Sci USA 2007; 104:16621-16626. (Pubitemid 350211066)
48. Yang Y, Dieter MZ, Chen Y, et al. Initial characterization of the glutamate-cysteine ligase modifier subunit Gclm(-/-) knockout mouse. Novel model system for a severely compromised oxidative stress response. J Biol Chem 2002; 277:49446-49452. (Pubitemid 36014379)
49. Steullet P, Cabungcal JH, Kulak A, et al. Redox dysregulation affects the ventral but not dorsal hippocampus: impairment of parvalbumin neurons, gamma oscillations, and related behaviors. J Neurosci 2010; 30:2547-2558.
50. Kulak A, Cuenod M, Do KQ. Behavioral phenotyping of glutathione-deficient mice: relevance to schizophrenia and bipolar disorder. Behav Brain Res 2012; 226:563-570.
51. -/-knockout mice. Neurotoxicol Teratol 2012; 34:450-457.
52. Das Neves Duarte JM, Kulak A, Gholam-Razaee MM, et al. N-acetylcysteine normalizes neurochemical changes in the glutathione-deficient schizophrenia mouse model during development. Biol Psychiatry 2012; 71:1006-1014.
53. Brandon NJ, Sawa A. Linking neurodevelopmental and synaptic theories of mental illness through DISC1. Nat Rev Neurosci 2011; 12:707-722.
54. Hikida T, Jaaro-Peled H, Seshadri S, et al. Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans. Proc Natl Acad Sci USA 2007; 104:14501-14506. (Pubitemid 350003290)
55. Hara MR, Agrawal N, Kim SF, et al. S-Nitrosylated GAPDH initiates apoptotic cell death by nuclear translocation following Siah1 binding. Nat Cell Biol 2005; 7:665-674. (Pubitemid 40975747)
56. Sen N, Hara MR, Kornberg MD, et al. Nitric oxide-induced nuclear GAPDH activates p300/CBP and mediates apoptosis. Nat Cell Biol 2008; 10:866-873. (Pubitemid 351934066)
57. Aoyama K, Suh SW, Hamby AM, et al. Neuronal glutathione deficiency and age-dependent neurodegeneration in the EAAC1 deficient mouse. Nat Neurosci 2006; 9:119-126. (Pubitemid 43011917)
58. Myles-Worsley M, Tiobech J, Browning SR, et al. Deletion at the SLC1A1 glutamate transporter gene co-segregates with schizophrenia and bipolar schizoaffective disorder in a 5-generation family. Am J Med Genet B Neuropsychiatr Genet 2013; 162B:87-95.
59. Horiuchi Y, Iida S, Koga M, et al. Association of SNPs linked to increased expression of SLC1A1 with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2012; 159B:30-37.
60. Hara MR, Thomas B, Cascio MB, et al. Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proc Natl Acad Sci USA 2006; 103:3887-3889. (Pubitemid 43376650)